Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Renal Cancer

Trial Name: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

Protocol ID: S0931

Eligibility:

 

Eligibility:

  • Patients must have histologically or cytologically confirmed renal cell carcinoma (clear cell or non-clear cell allowed, but collecting duct or medullary carcinomas excluded). 
  • Patients must have undergone a full surgical resection (radical nephrectomy or partial nephrectomy), including removal of all clinically positive nodes.
  • Patients must not have received any prior anti-cancer therapy (except for radical or partial nephrectomy noted above) for renal cell carcinoma, including systemic therapy in the adjuvant or neoadjuvant setting, immunotherapy, investigational therapy, surgical metastastectomy, or radiation therapy.
  • Patients must meet required laboratory values.
  • Patients must NOT have liver disease such as cirrhosis or severe hepatic impairment.
  • Patients must not have a known history of HIV seropositivity.
  • Patients must be able to take oral medications.  Patient may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  • All patients must be 18 years of age or older.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
  • Patients must not be pregnant or nursing due to animal studies that have shown reproductive toxicity effects.  Women/men of reproductive potential must have agreed to use an effective contraceptive method during protocol treatment and up to 8 weeks after ending protocol treatment. 

Enrollment: • About 1170 people will take part in this study at several medical centers.

Benefits:

 

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope the study drug will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about everolimus as a treatment for cancer.  This information could help future cancer patients.

Contact:

 

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope the study drug will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about everolimus as a treatment for cancer.  This information could help future cancer patients.

Created: Aug 17, 2011

Updated: Feb 24, 2014

« Return to Trials